Barriers may keep Merck’s new cholesterol drug from success
A long-awaited moment in preventive cardiology arrived last week, when enlicitide (which Merck is selling under the name…
Rare disease drugmakers seek exclusion from Medicare pricing plans
WASHINGTON — Biotech companies are lobbying the Trump administration to exclude treatments for rare diseases from programs that…
Novo Nordisk sues Eli Lilly over GLP-1 ads
Photo illustration of a group of weight loss medications on a white background. Ucg | Universal Images Group…
Iowa audit says PBMs turned accounting moves into millions in profit
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
What to know about testosterone replacement therapy
US Secretary of Defense Pete Hegseth speaks during a press briefing at the Pentagon in Washington, DC, on…
AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Market for psychedelic drugs to treat mental health gets a buy signal
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement…
Ozempic for cats? GLP-1 weight-loss drugs are coming for your fat pet
A beautiful, but over weight Maine Coon Cat gets measured around the belly by a vet. Ryersonclark |…
Natasha never expected to become addicted to prescribed opioids while battling endometriosis
Natasha Trajkovski was 21 when she was first prescribed opioids. After having a C-section, she was diagnosed with…
FDA signs off on Merck’s cholesterol-lowering pill
The US FDA approved Merck’s cholesterol-lowering pill, it said on Thursday, the first in a class of drugs dominated…
UnitedHealth Group (UNH) earnings Q2 2026
UnitedHealth Group on Thursday posted second-quarter earnings that blew past estimates and raised its full-year profit outlook, as…
Sales from controversial U.S. drug discount program rose to $100B last year
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…